Clinical Trials Logo
  1. Home
  2. Giant Cell Arteritis
  3. NCT04554290

Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy

Giant Cell Arteritis Clinical Trial

Official title:
Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy: a Monocentric Retrospective Study

Clinical Trial Summary

Temporal artery biopsy is a useful tool helping to the diagnosis of giant cell arteritis. However, other diagnoses might be associated with abnormal temporal artery biopsy. The purpose of this study is to describe the frequency of giant cell arteritis differential diagnoses with positive temporal artery biopsy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04554290
Study type Observational
Source Central Hospital, Nancy, France
Contact Thomas Moulinet, MD
Phone +33 3 83 15 53 04
Email t.moulinet@chru-nancy.fr
Status Recruiting
Phase
Start date August 1, 2020
Completion date September 30, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03812302 - Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) Phase 2
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Recruiting NCT05380453 - Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Phase 3
Recruiting NCT02333708 - Study of Circulating Microparticles in Giant Cell Arteritis
Completed NCT01450137 - Tocilizumab for Patients With Giant Cell Arteritis Phase 2
Completed NCT03827018 - KPL-301 for Subjects With Giant Cell Arteritis Phase 2
Active, not recruiting NCT04519580 - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting NCT04239196 - Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA Phase 2
Completed NCT03202368 - An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Phase 3
Not yet recruiting NCT02523625 - Giant Cell Arteritis: Improving Use of Ultrasound Evaluation N/A
Completed NCT03285945 - FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment N/A
Completed NCT02190916 - Vasculitis Illness Perception (VIP) Study N/A
Recruiting NCT01241305 - One-Time DNA Study for Vasculitis
Terminated NCT02531633 - Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Phase 3
Completed NCT03409913 - Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA N/A
Completed NCT03765424 - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Completed NCT01910038 - Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Phase 2
Not yet recruiting NCT04012905 - Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering Phase 3
Completed NCT03726749 - Tocilizumab Plus a Short Prednisone Taper for GCA Phase 4
Recruiting NCT05623592 - Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis Phase 2